# Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

> **NCT05814432** · PHASE3 · RECRUITING · sponsor: **Federal University of Health Science of Porto Alegre** · enrollment: 279 (estimated)

## Conditions studied

- Disseminated Histoplasma Capsulatum Infection
- AIDS and Infections
- Immunosuppression
- Fungal Infection

## Interventions

- **DRUG:** Single high dose of liposomal amphotericin B
- **DRUG:** L-AmB standard dose

## Key facts

- **NCT ID:** NCT05814432
- **Lead sponsor:** Federal University of Health Science of Porto Alegre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2026-08-28
- **Final completion:** 2026-11-28
- **Target enrollment:** 279 (ESTIMATED)
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814432, "Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05814432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*